Infliximab (Remicade®, Inflectra®, Renflexis®, Avsola™, Infliximab) Non-oncology

Covers infliximab for specified FDA‑approved and compendial off‑label non‑oncology indications (e.g., Crohn’s disease, ulcerative colitis, RA, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, Behçet’s, GVHD, hidradenitis suppurativa, juvenile idiopathic arthritis, pyoderma gangrenosum, sarcoidosis, scleritis, Still’s disease, other spondyloarthropathies, uveitis, and checkpoint inhibitor–related toxicities); indications not listed are excluded. Approvals require indication‑specific prior therapy trials and prescriber specialty/consultation, age limits where specified, minimum established therapy duration before re‑authorization (commonly 6 months, varies by indication), and documentation of objective or symptomatic benefit for renewals (note: mesalamine products and biosimilars do not count as systemic therapy for IBD).

"Crohn's disease"

Sign up to see full coverage criteria, indications, and limitations.